Natera and MyOme Launch Cutting-Edge Breast Cancer Risk Assessment Tool
Natera, Inc. (NASDAQ: NTRA), a leading player in the realm of genetic testing, has joined forces with MyOme to introduce a significant advancement in breast cancer risk evaluation known as the integrated polygenic risk score (iPRS). This innovative tool marks a pivotal movement toward personalized healthcare, particularly for women seeking a deeper understanding of their breast cancer risk.
Understanding the iPRS for Personalized Risk Assessment
The iPRS offers individuals personalized assessments based on a comprehensive evaluation of their genetics. This tool provides an estimate of breast cancer risk encompassing both a five-year and a lifetime perspective. Particularly notable is the fact that it serves individuals who have received a negative result from Natera’s Empower hereditary cancer test, offering them further insights into their potential risk.
The Importance of Polygenic Risk Scores
Unlike traditional risk assessments that focus on isolated genetic markers, polygenic risk scores calculate risks by analyzing multiple variants across an individual's entire genome. The iPRS integrates over one million single nucleotide polymorphisms (SNPs) with medical history inputs drawn from the Tyrer-Cuzick model, creating a holistic assessment. This approach not only enhances accuracy but also allows for a more diverse understanding of risk across different genetic backgrounds.
Research Backing the Efficacy of iPRS
A validation study highlighted in JCO Precision Oncology showcased the reliability of MyOme's iPRS, with over 130,000 women's data analyzed. The results indicated that the addition of iPRS could significantly refine breast cancer risk predictions compared to the conventional Tyrer-Cuzick model. An impressive 8% of the participants experienced a reclassification of their lifetime risk when evaluated with the iPRS, leading to more informed decision-making regarding proactive screening and risk management.
Proactive Screening and Personalized Health Care
With breast cancer affecting an estimated one in eight women in their lifetime, early detection remains critical. The iPRS benefits nearly 95% of the population who lack known pathogenic variants, facilitating timely and personalized healthcare approaches. By pinpointing those at elevated risk, healthcare practitioners can introduce proactive screening strategies, which may include heightened MRI screenings and adjusted mammography schedules.
Advancements in Predictive Healthcare
Leading the charge, Ramesh Hariharan, PhD, MBA, from Natera, expressed enthusiasm about this collaboration with MyOme, emphasizing the vital need for diverse ancestry consideration in breast cancer risk assessment. The integration of genetic information holds potential for profound impacts on women’s health management.
A Future of Personalized Risk Assessment
Echoing this sentiment, Akash Kumar, MD, PhD, from MyOme, articulated the drive toward merging clinical data and genomic analytics. His vision encompasses developing effective models for proactive health, enabling healthcare providers to tailor screening programs aiming for timely interventions in breast cancer cases. The introduction of iPRS is heralded as a stepping stone towards a future where predictive models can significantly improve health outcomes.
Eligibility for iPRS Services
The iPRS service is designed for individuals aged 18 to 85 who do not have a personal history of breast cancer and lack known mutations in any breast cancer-associated genes. This broad eligibility reinforces the tool’s potential to reach a wide demographic, encouraging more women to explore their genetic risk for breast cancer.
Frequently Asked Questions
What is the iPRS?
The integrated polygenic risk score (iPRS) is a tool designed to assess breast cancer risk based on multiple genetic factors and individual medical histories.
How does iPRS enhance breast cancer risk prediction?
iPRS significantly improves risk predictions by integrating over a million genetic variants, providing a comprehensive understanding of an individual's risk profile.
Who can benefit from the iPRS?
Women aged 18 to 85 without a personal history of breast cancer or known breast cancer gene mutations are eligible for the iPRS assessment.
Why is early detection important for breast cancer?
Early detection increases the chances of successful treatment and can lead to better health outcomes for individuals diagnosed with breast cancer.
How does Natera contribute to cancer risk assessment?
Natera combines advanced genetic testing and comprehensive data analysis to improve personalized healthcare solutions, enhancing early detection and risk management strategies in oncology.
